189 related articles for article (PubMed ID: 35875964)
1. Monitoring anti-CD19 chimeric antigen receptor T cell population by flow cytometry and its consistency with digital droplet polymerase chain reaction.
Cheng J; Mao X; Chen C; Long X; Chen L; Zhou J; Zhu L
Cytometry A; 2023 Jan; 103(1):16-26. PubMed ID: 35875964
[TBL] [Abstract][Full Text] [Related]
2. Optimization and validation of in vivo flow cytometry chimeric antigen receptor T cell detection method using CD19his indirect staining.
Zaninelli S; Meli C; Borleri G; Quaroni M; Pavoni C; Gaipa G; Biondi A; Introna M; Golay J; Rambaldi A; Rambaldi B
Cytometry A; 2024 Feb; 105(2):112-123. PubMed ID: 37707318
[TBL] [Abstract][Full Text] [Related]
3. Detection and Quantification of Chimeric Antigen Receptor Transgene Copy Number by Droplet Digital PCR versus Real-Time PCR.
Lou Y; Chen C; Long X; Gu J; Xiao M; Wang D; Zhou X; Li T; Hong Z; Li C; Zhou J; Chen L
J Mol Diagn; 2020 May; 22(5):699-707. PubMed ID: 32409121
[TBL] [Abstract][Full Text] [Related]
4. Droplet digital PCR allows vector copy number assessment and monitoring of experimental CAR T cells in murine xenograft models or approved CD19 CAR T cell-treated patients.
Haderbache R; Warda W; Hervouet E; da Rocha MN; Trad R; Allain V; Nicod C; Thieblemeont C; Boissel N; Varlet P; Agha IY; Bouquet L; Guiot M; Venet F; Sujobert P; Roussel X; Rouzaire PO; Caillot D; Casasnovas O; Bories JC; Bachy E; Caillat-Zucman S; Deschamps M; Ferrand C
J Transl Med; 2021 Jun; 19(1):265. PubMed ID: 34154602
[TBL] [Abstract][Full Text] [Related]
5. [Maintenance therapy following CD19 CAR-T treatment for relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
Jiang YL; Li Q; Pu YD; Jiang YY; Yuan T; Deng Q; Li YM; Han MZ; Zhai WH
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):495-501. PubMed ID: 32654464
[No Abstract] [Full Text] [Related]
6. Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials.
Ramanayake S; Bilmon I; Bishop D; Dubosq MC; Blyth E; Clancy L; Gottlieb D; Micklethwaite K
Cytotherapy; 2015 Sep; 17(9):1251-67. PubMed ID: 26212611
[TBL] [Abstract][Full Text] [Related]
7. Digital polymerase chain reaction strategies for accurate and precise detection of vector copy number in chimeric antigen receptor T-cell products.
Murphy LA; Marians RC; Miller K; Brenton MD; Mallo RLV; Kohler ME; Fry TJ; Winters AC
Cytotherapy; 2023 Jan; 25(1):94-102. PubMed ID: 36253252
[TBL] [Abstract][Full Text] [Related]
8. Insights on Droplet Digital PCR-Based Cellular Kinetics and Biodistribution Assay Support for CAR-T Cell Therapy.
Sugimoto H; Chen S; Minembe JP; Chouitar J; He X; Wang H; Fang X; Qian MG
AAPS J; 2021 Mar; 23(2):36. PubMed ID: 33655393
[TBL] [Abstract][Full Text] [Related]
9. Digital-Droplet PCR for Quantification of CD19-Directed CAR T-Cells.
Mika T; Maghnouj A; Klein-Scory S; Ladigan-Badura S; Baraniskin A; Thomson J; Hasenkamp J; Hahn SA; Wulf G; Schroers R
Front Mol Biosci; 2020; 7():84. PubMed ID: 32500079
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD79b/CD3 bispecific antibody combined with CAR19-T cells for B-cell lymphoma treatment.
Zheng WW; Zhou H; Li P; Ye SG; Abudureheman T; Yang LT; Qing K; Liang AB; Chen KM; Duan CW
Cancer Immunol Immunother; 2023 Nov; 72(11):3739-3753. PubMed ID: 37707586
[TBL] [Abstract][Full Text] [Related]
11. Comparison of FACS and PCR for Detection of BCMA-CAR-T Cells.
Reichman A; Kunz A; Joedicke JJ; Höpken UE; Keib A; Neuber B; Sedloev D; Wang L; Jiang G; Hückelhoven-Krauss A; Eberhardt F; Müller-Tidow C; Wermke M; Rehm A; Schmitt M; Schmitt A
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055086
[TBL] [Abstract][Full Text] [Related]
12. Application of droplet digital PCR for the detection of vector copy number in clinical CAR/TCR T cell products.
Lu A; Liu H; Shi R; Cai Y; Ma J; Shao L; Rong V; Gkitsas N; Lei H; Highfill SL; Panch S; Stroncek DF; Jin P
J Transl Med; 2020 May; 18(1):191. PubMed ID: 32384903
[TBL] [Abstract][Full Text] [Related]
13. PiggyBac-Engineered T Cells Expressing CD19-Specific CARs that Lack IgG1 Fc Spacers Have Potent Activity against B-ALL Xenografts.
Bishop DC; Xu N; Tse B; O'Brien TA; Gottlieb DJ; Dolnikov A; Micklethwaite KP
Mol Ther; 2018 Aug; 26(8):1883-1895. PubMed ID: 29861327
[TBL] [Abstract][Full Text] [Related]
14. Bioanalytical Methods for Characterization of CAR-T Cellular Kinetics: Comparison of PCR Assays and Matrices.
Masilamani M; Jawa V; Dai Y; Das R; Park A; Lamba M; Wu F; Zheng X; Lu E; Gleason C; Mack T; Mora J; Surapaneni S
Clin Pharmacol Ther; 2023 Sep; 114(3):664-672. PubMed ID: 37422675
[TBL] [Abstract][Full Text] [Related]
15. A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors.
De Oliveira SN; Wang J; Ryan C; Morrison SL; Kohn DB; Hollis RP
J Transl Med; 2013 Jan; 11():23. PubMed ID: 23360526
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities.
Vasic D; Lee JB; Leung Y; Khatri I; Na Y; Abate-Daga D; Zhang L
Sci Immunol; 2022 Apr; 7(70):eabl3642. PubMed ID: 35452255
[TBL] [Abstract][Full Text] [Related]
17. A cell-based immunogenicity assay to detect antibodies against chimeric antigen receptor expressed by tisagenlecleucel.
Potthoff B; McBlane F; Spindeldreher S; Sickert D
J Immunol Methods; 2020 Jan; 476():112692. PubMed ID: 31678267
[TBL] [Abstract][Full Text] [Related]
18. Advanced Flow Cytometry Assays for Immune Monitoring of CAR-T Cell Applications.
Blache U; Weiss R; Boldt A; Kapinsky M; Blaudszun AR; Quaiser A; Pohl A; Miloud T; Burgaud M; Vucinic V; Platzbecker U; Sack U; Fricke S; Koehl U
Front Immunol; 2021; 12():658314. PubMed ID: 34012442
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of Circulating CAR T Cells: Validation of a Flow Cytometric Assay, Cellular Kinetics, and Phenotype Analysis Following Tisagenlecleucel.
Peinelt A; Bremm M; Kreyenberg H; Cappel C; Banisharif-Dehkordi J; Erben S; Rettinger E; Jarisch A; Meisel R; Schlegel PG; Beck O; Bug G; Klusmann JH; Klingebiel T; Huenecke S; Bader P
Front Immunol; 2022; 13():830773. PubMed ID: 35309367
[TBL] [Abstract][Full Text] [Related]
20. CAR19/22 T cell cocktail therapy for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation.
Yan N; Wang N; Wang G; Huang L; Li C; Wang D; Wang J; Huang L; Meng F; Wei J; Chen L; Mao X; Zhou J; Zhang Y; Cao Y
Cytotherapy; 2022 Aug; 24(8):841-849. PubMed ID: 35256277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
